Quarterly ResultMay 14, 2026, 05:16 PM
Nuo Therapeutics Q1 Revenue +169% to $1.3M; Operating Loss Reduced
AI Summary
Nuo Therapeutics announced strong financial results for Q1 2026, with total revenues increasing by 169% year-over-year to approximately $1.3 million. The company also significantly reduced its net operating loss to $446,000 from $745,000 in the prior year. Nuo reported robust demand for its Aurix product and favorable market response to improved Medicare reimbursement. Additionally, the company secured a $1.0 million Loan and Security Agreement to support growth and working capital.
Key Highlights
- Total revenues increased 169% to approximately $1.3 million in Q1 2026.
- Product revenues were approximately $1,224,000 for the first quarter of 2026.
- Aurix branded product revenues grew over 30% sequentially from Q4 2025.
- Net operating loss decreased to approximately $446,000 from $745,000 year-over-year.
- Net loss improved to $(618,466) from $(746,128) in the prior year quarter.
- Entered a Loan and Security Agreement with initial funding of $1.0 million.
- Cash balance was $263,827 as of March 31, 2026.
- Total assets increased to $1,945,669 as of March 31, 2026.
Price Impact
More from AURX